Bulletin
Investor Alert

press release

Jan. 3, 2022, 7:01 a.m. EST

Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. /zigman2/quotes/202103251/composite APLS -4.21% , a global biopharmaceutical company and leader in complement, today announced that the company will present virtually at the 40 [th] Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.

The presentation and question and answer session will be available via a live webcast from the " Events and Presentations " page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 30 days following the event. A copy of the presentation slides will be also posted on the company's website beginning on Monday, January 10, 2022, at 8:00 a.m. ET.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com .

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com 
617.599.8178

COMTEX_399973693/2471/2022-01-03T07:00:41

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/202103251/composite
US : U.S.: Nasdaq
$ 42.55
-1.87 -4.21%
Volume: 746,476
May 24, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.73 billion
Rev. per Employee
$170,050
loading...

Partner Center

Link to MarketWatch's Slice.